

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAPLUS with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS EXPRESS		JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:49:20 ON 20 JAN 2006

=> file reg

FILE 'REGISTRY' ENTERED AT 14:49:30 ON 20 JAN 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JAN 2006 HIGHEST RN 872163-75-2
 DICTIONARY FILE UPDATES: 18 JAN 2006 HIGHEST RN 872163-75-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information.  *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details..

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s 198218-79-0/rn
L1      1 198218-79-0/RN

=> s 191856-33-4/rn
L2      1 191856-33-4/RN


=> s (88607-26-5 OR 88607-27-6)/rn
      1 88607-26-5/RN
      1 88607-27-6/RN
L3      2 (88607-26-5 OR 88607-27-6)/RN

=> s 311797-64-5/rn
L4      1 311797-64-5/RN

=> d ll str cbib
```

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REFERENCE 1: 136:151066 Asymmetric Syntheses of Fused Bicyclic Lactams.
Lim, Sung H.; Ma, Sunghoon; Beak, Peter (Department of Chemistry,
University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA).
Journal of Organic Chemistry, 66(26), 9056-9062 (English) 2001. CODEN:
JOCEAH. ISSN: 0022-3263. Publisher: American Chemical Society.

REFERENCE 2: 127:358978 Synthesis of chiral bicyclic lactams using
ring-closure metathesis. Synthesis of (-)-coniceine and (S)-pyrrolam A.
Arisawa, Mitsuhiro; Takezawa, Emiko; Nishida, Atsushi; Mori, Miwako;
Nakagawa, Masako (Faculty Pharmaceutical Sciences, Chiba University,
Chiba, 263, Japan). Synlett (10), 1179-1180 (English) 1997. CODEN:
SYNLES. ISSN: 0936-5214. Publisher: Thieme.

=> d 12 str cbib

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REFERENCE 1: 127:81322 Fluoro-lactonization of 4-alkenoic acid derivatives
with N-fluoropentachloropyridinium triflate. Okada, Midori; Nakamura,
Yuko; Horikawa, Hiroaki; Inoue, Tadashi; Taguchi, Takeo (Tokyo Women's
Medical College, Tokyo, 162, Japan). Journal of Fluorine Chemistry,
82(2), 157-161 (English) 1997. CODEN: JFLCAR. ISSN: 0022-1139.
Publisher: Elsevier.

=> d 13 str cbib 1-2


L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REFERENCE 1: 100:64931 Organic natural products. Part 188. Structure of hypercratine, another alkaloid of *Ruspolia hypercrateriformis*. Neukomm, G.; Roessler, F.; Johne, S.; Hesse, M. (Org.-Chem. Inst., Univ. Zurich, Zurich, CH-8057, Switz.). *Planta Medica*, 48(4), 246-52 (German) 1983. CODEN: PLMEAA. ISSN: 0032-0943.

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REFERENCE 1: 100:64931 Organic natural products. Part 188. Structure of hypercratine, another alkaloid of *Ruspolia hypercrateriformis*. Neukomm, G.; Roessler, F.; Johne, S.; Hesse, M. (Org.-Chem. Inst., Univ. Zurich, Zurich, CH-8057, Switz.). *Planta Medica*, 48(4), 246-52 (German) 1983. CODEN: PLMEAA. ISSN: 0032-0943.

=> d 14 str cbib

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



REFERENCE 1: 136:151066 Asymmetric Syntheses of Fused Bicyclic Lactams.
Lim, Sung H.; Ma, Sunghoon; Beak, Peter (Department of Chemistry,
University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA).
Journal of Organic Chemistry, 66(26), 9056-9062 (English) 2001. CODEN:
JOCEAH. ISSN: 0022-3263. Publisher: American Chemical Society.

REFERENCE 2: 134:42302 Construction of chiral 1,2-cycloalkanopyrrolidines
from L-proline using ring closing metathesis (RCM). Arisawa, Mitsuhiro;
Takahashi, Maki; Takezawa, Emiko; Yamaguchi, Takenobu; Torisawa, Yasuhiro;
Nishida, Atsushi; Nakagawa, Masako (Faculty of Pharmaceutical Sciences,
Chiba University, Chiba, 263-8522, Japan). Chemical & Pharmaceutical
Bulletin, 48(10), 1593-1596 (English) 2000. CODEN: CPBTAL. ISSN:
0009-2363. Publisher: Pharmaceutical Society of Japan.

=>

Uploading C:\Program Files\Stnexp\Queries\10686871.str

Cy



chain nodes :

6 7 9 10 11

ring nodes :

1 2 3 4 5

ring/chain nodes :

8

chain bonds :

3-6 4-9 6-7 6-8 9-10 10-11

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

2-3 3-4 3-6 6-7 9-10 10-11

exact bonds :

1-2 1-5 4-5 4-9 6-8

isolated ring systems :
containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:Atom

L5 STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 14:53:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5579 TO ITERATE

35.8% PROCESSED 2000 ITERATIONS 14 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 107102 TO 116058
PROJECTED ANSWERS: 407 TO 1155

L6 14 SEA SSS SAM L5

=> d scan

L6 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Pyrrolidineethanol, 1-(2,2-dimethyl-1-oxopropyl)- α -phenyl-,
(R*,S*)- (9CI)
MF C17 H25 N O2

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L6 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-
[(cyclopropylamino)acetyl]-, (S)- (9CI)
MF C22 H31 N5 O


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6 14 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- α -(2-hydroxyethyl)-, stereoisomer (9CI)
 MF C26 H37 N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 15 full

FULL SEARCH INITIATED 14:54:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 114091 TO ITERATE

100.0% PROCESSED 114091 ITERATIONS

634 ANSWERS

SEARCH TIME: 00.00.07

L7 634 SEA SSS FUL L5

=> s 17 not 11 not 12 not 13 not 14

L8 629 L7 NOT L1 NOT L2 NOT L3 NOT L4

=> file caplus; s l8; s wo2001034567/pn
 FILE 'CAPLUS' ENTERED AT 14:55:39 ON 20 JAN 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jan 2006 VOL 144 ISS 5
 FILE LAST UPDATED: 19 Jan 2006 (20060119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

L9 83 L8

L10 2 WO2001034567/PN
 (WO2001034567/PN)

=> s l9 not l10
 L11 81 L9 NOT L10

=> d l10 1 cbib hitstr

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 2004:372866 Document No. 140:391195 Preparation of N-acylpyrrolidin-2-ylalkylbenzamidines as factor Xa inhibitors. Czekaj, Mark; Klein, Scott I.; Pauls, Heinz W. (Aventis Pharma Deutschland GmbH, Germany). U.S. Pat. Appl. Publ. US 2004087570 A1 20040506, 37 pp., Cont.-in-part of U.S. Ser. No. 143,190, abandoned. (English). CODEN: USXXCO. APPLICATION: US 2003-686871 20031016. PRIORITY: US 1999-PV164621 19991110; GB 1999-30540 19991223; WO 2000-EP10890 20001104; US 2002-2002/143190 20020510.

=> d l10 2 cbib pi hitstr

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 2001:359962 Document No. 134:366794 Preparation of amidinophenyl(aroilpyrrolidinyl)propionates and analogs as factor Xa inhibitors. Czekaj, Mark; Klein, Scott I.; Pauls, Heinz W. (Aventis Pharma Deutschland G.m.b.H., Germany). PCT Int. Appl. WO 2001034567 A1 20010517, 91 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI,

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2000-EP10890 20001104. PRIORITY: US 1999-PV164621 19991110; GB 1999-30540 19991223.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001034567	A1	20010517	WO 2000-EP10890	20001104 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2390858	AA	20010517	CA 2000-2390858	20001104
EP 1263726	A1	20021211	EP 2000-984965	20001104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003513957	T2	20030415	JP 2001-536516	20001104
US 2003092698	A1	20030515	US 2002-143190	20020510
US 2004087570	A1	20040506	US 2003-686871	20031016

=> help display

The DISPLAY command is used to view various types of saved and current-session information. To use this command, enter DISPLAY and the name of the item to be displayed. The system will display the item online. Highlighting characters may be suppressed by adding the NOHIGHLIGHT (NOH) option on the command line.

For information on the predefined formats available for the display of records in this file, enter HELP FORMAT at an arrow prompt (=>). For information on the display of records using individual fields or groups of fields, enter HELP DFIELDS. For information on how to create a user-defined display format, enter HELP SET FORMAT. For information on how to change the default display format for this file, enter HELP SET DFORMAT. To see the current default display format for this file, enter DISPLAY SET DFORMAT.

For more information about the DISPLAY command, enter one of the following HELP commands at an arrow prompt.

=> HELP DISPLAY ACC ----- To see the record for a specific Accession Number in a file

=> HELP DISPLAY ARCHIVE --- To grant permission to store STN records for the purposes of electronic access by a specified number of users within your worldwide organization

=> HELP DISPLAY BROWSE ---- To browse through an answer set without

rekeying the DISPLAY command before each answer number

- => HELP DISPLAY CLUSTER --- To see user-defined and system-defined file clusters
- => HELP DISPLAY COST ----- To see the approximate cost of a session
- => HELP DISPLAY CURRENCY -- To see the patent currency status of certain files
- => HELP DISPLAY EXPAND ----- To see the E-number list from an EXPAND or SELECT command
- => HELP DISPLAY FIELD ----- To see the user-defined search fields
- => HELP DISPLAY FORMAT ----- To see the user-defined display formats
- => HELP DISPLAY FROM ----- To see records from specific files when the L-number contains records from multiple files
- => HELP DISPLAY HISTORY --- To see the commands used in this session
- => HELP DISPLAY L# ----- To see answers from a search
- => HELP DISPLAY PFAM ----- To see selective records from specified patent families in an FSORT L-number
- => HELP DISPLAY PRINT ----- To see the status of offline prints requested in this session
- => HELP DISPLAY QUERY ----- To see the definition of a query
- => HELP DISPLAY REDISTRIBUTE -- To grant permission to redistribute within your worldwide organization a specified number of printed or electronic copies of STN records
- => HELP DISPLAY SAVED ----- To list saved items for this loginid
- => HELP DISPLAY SCAN ----- To scan through an answer set in random order with a predefined display format
- => HELP DISPLAY SELECT ----- To see the E-number list from a SELECT or EXPAND command
- => HELP DISPLAY SET ----- To see the SET parameters currently active, changed, or set permanently
- => HELP DISPLAY TERM ----- To see the terms extracted using SmartSELECT
- => HELP DISPLAY TOLERANCE - To see the tolerance in effect for numeric fields available in the current file
- => HELP DISPLAY TSORT ----- To sort the entries in a display that

uses a table format

=> HELP DISPLAY UNIT ----- To see the units in effect for numeric fields available in the current file

=>

=> s 19 and 110

L12 2 L9 AND L10

=> d 112 2 cbib pi hitstr

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

2001:359962 Document No. 134:366794 Preparation of

amidinophenyl(aroylpyrrolidinyl)propionates and analogs as factor Xa inhibitors. Czekaj, Mark; Klein, Scott I.; Pauls, Heinz W. (Aventis Pharma Deutschland G.m.b.H., Germany). PCT Int. Appl. WO 2001034567 A1 20010517, 91 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2000-EP10890 20001104. PRIORITY: US 1999-PV164621 19991110; GB 1999-30540 19991223.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001034567	A1	20010517	WO 2000-EP10890	20001104 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2390858	AA	20010517	CA 2000-2390858	20001104
EP 1263726	A1	20021211	EP 2000-984965	20001104
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
JP 2003513957	T2	20030415	JP 2001-536516	20001104
US 2003092698	A1	20030515	US 2002-143190	20020510
US 2004087570	A1	20040506	US 2003-686871	20031016

IT 340040-25-7P 340040-27-9P 340040-29-1P
 340040-31-5P 340040-33-7P 340040-35-9P
 340040-37-1P 340040-39-3P 340040-41-7P
 340040-43-9P 340040-44-0P 340040-45-1P
 340040-47-3P 340040-49-5P 340040-51-9P
 340040-53-1P 340040-55-3P 340040-57-5P
 340040-59-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amidinophenyl(aroylpyrrolidinyl)propionates and analogs as factor Xa inhibitors)


RN 340040-25-7 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-
 ([1,1'-biphenyl]-4-ylcarbonyl)-, methyl ester, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)

CM 1

CRN 340040-24-6


CMF C28 H29 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 340040-27-9 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-
 [4-(3-pyridinyl)benzoyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA
 INDEX NAME)

CM 1

CRN 340040-26-8


CMF C27 H28 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 340040-29-1 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl)methyl]-1-
[[3'-(aminomethyl)[1,1'-biphenyl]-4-yl]carbonyl]-, methyl ester,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-28-0


CMF C29 H32 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 340040-31-5 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-
 [(6-chlorobenzo[b]thien-2-yl)carbonyl]-, methyl ester,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-30-4


CMF C24 H24 Cl N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 340040-33-7 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-[4-(6-methoxy-3-pyridinyl)benzoyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-32-6


CMF C28 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 340040-35-9 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-34-8


CMF C27 H28 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-37-1 CAPLUS


CN 2-Pyrrolidineacetic acid, α -[[4-(aminoiminomethyl)phenyl]methyl]-1-[[1,1'-biphenyl]-4-ylcarbonyl]-, methyl ester, mono(trifluoroacetate)

(9CI) (CA INDEX NAME)

CM 1

CRN 340040-36-0


CMF C28 H29 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-39-3 CAPLUS


CN 1H-Pyrrolo[3,2-c]pyridine-2-propanoic acid, α -[(2R)-1-([1,1'-biphenyl]-4-ylcarbonyl)-2-pyrrolidinyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-38-2

CMF C28 H27 N3 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-41-7 CAPLUS


CN 1H-Pyrrolo[2,3-c]pyridine-2-propanoic acid, α -[(2R)-1-([1,1'-biphenyl]-4-ylcarbonyl)-2-pyrrolidinyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-40-6

CMF C28 H27 N3 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-43-9 CAPLUS


CN 6-Quinazolinepropanoic acid, 4-amino- α -[1-([1,1'-biphenyl]-4-ylcarbonyl)-2-pyrrolidinyl]-, methyl ester, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 340040-42-8

CMF C29 H28 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 340040-44-0 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, methyl ester, (α R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 340040-45-1 CAPLUS


CN 2-Pyrrolidineacetic acid, α-[[3-(aminoiminomethyl)phenyl]methyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, methyl ester, (αR,2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-44-0

CMF C27 H28 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-47-3 CAPLUS


CN 2-Pyrrolidineacetic acid, α -[[5-(aminoiminomethyl)-2-hydroxyphenyl]methyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, methyl ester, (α R,2R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-46-2

CMF C27 H28 N4 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 340040-49-5 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-([1,1'-biphenyl]-4-ylcarbonyl)-, methyl ester, (α R,2R)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 340040-48-4
CMF C28 H29 N3 O3

Relative stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 340040-51-9 CAPLUS
CN Pyrrolidine, 2-[2-[3-(aminoiminomethyl)phenyl]ethyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 340040-50-8
CMF C25 H26 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-53-1 CAPLUS


CN Pyrrolidine, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethenyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, (2R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-52-0

CMF C25 H24 N4 O3


Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-55-3 CAPLUS


CN Pyrrolidine, 2-[2-[5-(aminoiminomethyl)-2-hydroxyphenyl]ethyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-54-2

CMF C25 H26 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 340040-57-5 CAPLUS


CN 2-Pyrrolidineacetic acid, α -[[3-(aminoiminomethyl)phenyl]methyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, (α R,2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-56-4

CMF C26 H26 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 340040-59-7 CAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-propanoic acid, α -[1-([1,1'-biphenyl]-4-ylcarbonyl)-2-pyrrolidinyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 340040-58-6


CMF C28 H27 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 340040-60-0P 340040-62-2P 340040-63-3P
 340040-64-4P 340040-65-5P 340040-66-6P
 340040-69-9P 340040-71-3P 340040-77-9P
 340040-79-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of amidinophenyl(aroylpyrrolidinyl)propionates and analogs as
 factor Xa inhibitors)


RN 340040-60-0 CAPLUS

CN 2-Pyrrolidineacetic acid, 1-([1,1'-biphenyl]-4-ylcarbonyl)- α -[(3-
 cyanophenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 340040-62-2 CAPLUS

CN 2-Pyrrolidineacetic acid, α-[(3-cyanophenyl)methyl]-1-[4-(3-pyridinyl)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 340040-63-3 CAPLUS

CN 2-Pyrrolidineacetic acid, α-[[3-(aminoiminomethyl)phenyl]methyl]-1-[[3'-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 340040-64-4 CAPLUS

CN 2-Pyrrolidineacetic acid, 1-[(6-chlorobenzo[b]thien-2-yl)carbonyl]-α-[(3-cyanophenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 340040-65-5 CAPLUS

CN 2-Pyrrolidineacetic acid, α-[(3-cyanophenyl)methyl]-1-[4-(6-methoxy-3-pyridinyl)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 340040-66-6 CAPLUS


CN 2-Pyrrolidineacetic acid, 1-([1,1'-biphenyl]-4-ylcarbonyl)-α-[(4-cyanophenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 340040-69-9 CAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine-2-propanoic acid, α-[(2R)-1-([1,1'-biphenyl]-4-ylcarbonyl)-2-pyrrolidinyl]-1-[(1,1-dimethylethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 340040-71-3 CAPLUS

CN 6-Quinazolinepropanoic acid, α -[(2R)-1-([1,1'-biphenyl]-4-ylcarbonyl)-2-pyrrolidinyl]-4-chloro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 340040-77-9 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[5-cyano-2-[2-(methoxymethoxy)ethoxy]phenyl]methyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, methyl ester, (α R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 340040-79-1 CAPLUS

CN 2-Pyrrolidineacetic acid, α -[[5-(aminoiminomethyl)-2-[2-(methoxymethoxy)ethoxy]phenyl]methyl]-1-[4-(1,6-dihydro-6-oxo-3-pyridinyl)benzoyl]-, methyl ester, (α R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s l11 and p/dt

5096131 P/DT

L13 38 L11 AND P/DT

=> sort l13 py

SORT ENTIRE ANSWER SET? (Y)/N:.

PROCESSING COMPLETED FOR L13


L14 38 SORT L13 PY

=> d 1-10 pi fhitstr


L14 ANSWER 1 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3891616	A	19750624	US 1974-461669	19740417
IT	57282-26-5P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of)				
RN	57282-26-5	CAPLUS			
CN	Bradykinin, 2-L-2-pyrrolidineacetic acid- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L14	ANSWER 2 OF 38	CAPLUS	COPYRIGHT 2006	ACS on STN	
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 330108	A1	19890830	EP 1989-102859	19890218
	EP 330108	B1	19951227		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ZA 8900986	A	19891025	ZA 1989-986	19890208
	AU 8929838	A1	19890824	AU 1989-29838	19890210
	DK 8900667	A	19890823	DK 1989-667	19890213
	FI 8900689	A	19890823	FI 1989-689	19890214
	US 4923857	A	19900508	US 1989-312061	19890217
	AT 132150	E	19960115	AT 1989-102859	19890218
	NO 8900723	A	19890823	NO 1989-723	19890221
	HU 49612	A2	19891030	HU 1989-839	19890221
	CN 1037149	A	19891115	CN 1989-100880	19890221
	JP 02001490	A2	19900105	JP 1989-42769	19890222
	JP 2748500	B2	19980506		

US 5081237 A 19920114 US 1990-472270 19900130
 IT **126408-80-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of antibacterial)
 RN 126408-80-8 CAPLUS
 CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[1-[[[(1,1-
 dimethylethyl)dimethylsilyl]oxy]ethyl]-3-[1-methyl-2-[1-[[methyl[(2-
 propenyloxy)carbonyl]amino]acetyl]-2-pyrrolidinyl]ethenyl]-7-oxo-,
 2-propenyl ester, [5R-[3(S*),5 α ,6 α (R*)]]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



L14 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN
 PATENT NO. KIND DATE APPLICATION NO. DATE


 PI DD 294176 A5 19910926 DD 1990-340569 19900511
 IT **139191-55-2P**
 RL: PREP (Preparation)
 (preparation of, as selective and reversible inhibitors of
 prolylendopeptidase)
 RN 139191-55-2 CAPLUS
 CN Pyridinium, 1-[2-oxo-2-[1-[[1-[(phenylmethoxy)carbonyl]-2-
 pyrrolidinyl]carbonyl]-2-pyrrolidinyl]ethyl]-, chloride, [S-(R*,R*)]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● Cl⁻

L14 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9316999	A1	19930902	WO 1993-GB404	19930226
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
GB 2264492	A1	19930901	GB 1992-4221	19920227
GB 2264492	B2	19960925		
AU 9336391	A1	19930913	AU 1993-36391	19930226
AU 672390	B2	19961003		
EP 628033	A1	19941214	EP 1993-905480	19930226
EP 628033	B1	20030723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07505121	T2	19950608	JP 1993-506433	19930226
JP 2571344	B2	19970116		
RU 2139282	C1	19991010	RU 1994-38255	19930226
AT 245632	E	20030815	AT 1993-905480	19930226
CA 2129990	C	20060110	CA 1993-2129990	19930226
NO 9403133	A	19940824	NO 1994-3133	19940824
NO 311215	B1	20011029		
FI 9403941	A	19941026	FI 1994-3941	19940826
US 5688943	A	19971118	US 1994-284462	19940914
IT 152665-78-6				
RL: RCT (Reactant); RACT (Reactant or reagent) (preparation cholecystokinin and gastrin receptor antagonist activity of)				
RN 152665-78-6	CAPLUS			
CN	Pyrrolidine, 1-acetyl-2-[[2,3-dihydro-3-[[[(3-methylphenyl)amino]carbonyl]amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)			




L14 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2264492	A1	19930901	GB 1992-4221	19920227
	GB 2264492	B2	19960925		
	IL 104853	A1	19971120	IL 1993-104853	19930225
	WO 9316999	A1	19930902	WO 1993-GB404	19930226
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9336391	A1	19930913	AU 1993-36391	19930226
	AU 672390	B2	19961003		
	ZA 9301381	A	19931215	ZA 1993-1381	19930226
	EP 628033	A1	19941214	EP 1993-905480	19930226
	EP 628033	B1	20030723		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 67963	A2	19950529	HU 1994-2212	19930226
	JP 07505121	T2	19950608	JP 1993-506433	19930226
	JP 2571344	B2	19970116		
	RU 2139282	C1	19991010	RU 1994-38255	19930226
	AT 245632	E	20030815	AT 1993-905480	19930226
	EP 1342719	A1	20030910	EP 2003-10776	19930226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	PT 628033	T	20031231	PT 1993-905480	19930226
	ES 2203616	T3	20040416	ES 1993-905480	19930226
	CA 2129990	C	20060110	CA 1993-2129990	19930226
	CN 1075717	A	19930901	CN 1993-101848	19930227
	CN 1051079	B	20000405		
	TW 438783	B	20010607	TW 1993-82102213	19930324
	NO 9403133	A	19940824	NO 1994-3133	19940824
	NO 311215	B1	20011029		
	FI 9403941	A	19941026	FI 1994-3941	19940826
	US 5688943	A	19971118	US 1994-284462	19940914
	US 5962451	A	19991005	US 1997-867422	19970606

IT **152665-78-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and cholecystokinin-B and gastrin receptor antagonists activity of)


RN 152665-78-6 CAPLUS
 CN Pyrrolidine, 1-acetyl-2-[[[2,3-dihydro-3-[[[(3-methylphenyl)amino]carbonyl]amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9745424	A1	19971204	WO 1997-KR100	19970531
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9730494	A1	19980105	AU 1997-30494	19970531
	EP 918768	A1	19990602	EP 1997-925316	19970531
	EP 918768	B2	20020109		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	CN 1219932	A	19990616	CN 1997-195005	19970531
	CN 1079396	B	20020220		
	JP 2000504030	T2	20000404	JP 1997-542065	19970531
	JP 3202994	B2	20010827		
	AT 211741	E	20020115	AT 1997-925316	19970531
	ES 2171945	T3	20020916	ES 1997-925316	19970531
	CA 2256438	C	20021015	CA 1997-2256438	19970531
	CA 2256438	AA	19971204		
	US 6201006	B1	20010313	US 1998-180675	19981113
IT	200182-50-9P				
	RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(preparation of indolecarboxamides and analogs as thrombin inhibitors)			
RN	200182-50-9	CAPLUS			
CN	Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-(4-methoxybenzoyl)-, (S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L14	ANSWER 7 OF 38	CAPLUS	COPYRIGHT 2006	ACS on STN	
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9736869	A1	19971009	WO 1997-US4916	19970324
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5717092	A	19980210	US 1996-626259	19960329
	CA 2249369	AA	19971009	CA 1997-2249369	19970324
	AU 9723465	A1	19971022	AU 1997-23465	19970324
	EP 891331	A1	19990120	EP 1997-916231	19970324
	EP 891331	B1	20031001		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2000507578	T2	20000620	JP 1997-535395	19970324
	AT 251140	E	20031015	AT 1997-916231	19970324
	PT 891331	T	20040227	PT 1997-916231	19970324
	ES 2208890	T3	20040616	ES 1997-916231	19970324
	US 5935954	A	19990810	US 1997-961551	19971030

IT 198131-70-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of N-(aryloxalyl)piperidine-2-carboxylates and analogs as multidrug resistance inhibitors)

RN 198131-70-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(1-acetyl-4-ethoxy-2-pyrrolidinyl)oxoacetyl]-, 1-[5-[1-(2-methoxyethylidene)butyl]-3-pyridinyl]-3-(4-morpholinyl)propyl ester, [2S-[2 α [R*[S*(Z)]]],4 β]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L14 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9712903	A1	19970410	WO 1996-US15998	19961002
	W:	AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	AU 9673926	A1	19970428	AU 1996-73926	19961002
	ZA 9608334	A	19970513	ZA 1996-8334	19961003
	US 5922697	A	19990713	US 1998-51038	19980331


IT 188196-59-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of compds. and compns. for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins)

RN 188196-59-0 CAPLUS

CN 1-Pyrrolidinepentanoic acid, γ -[[2-(acetylamino)-1-oxo-3-[4-(phosphonooxy)phenyl]propyl]amino]- δ -oxo-2-(2-phenylethyl)-, [2R-[1[S*(S*)],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14	ANSWER 9 OF 38	CAPLUS	COPYRIGHT 2006	ACS on STN	
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9840400	A1	19980917	WO 1998-US4317	19980305
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5965537	A	19991012	US 1997-814577	19970310
	CA 2297164	AA	19980917	CA 1998-2297164	19980305
	AU 9864482	A1	19980929	AU 1998-64482	19980305
	AU 744511	B2	20020228		
	EP 981539	A1	20000301	EP 1998-910182	19980305
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE, FI				
	BR 9808017	A	20000308	BR 1998-8017	19980305
	JP 2001518084	T2	20011009	JP 1998-539630	19980305
	ZA 9801957	A	19990909	ZA 1998-1957	19980309
	TW 505657	B	20021011	TW 1998-87103515	19980310
	NO 9904364	A	19991109	NO 1999-4364	19990909

IT **213328-90-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of Dolastatin derivs. with carbonyl and heterocyclyl moieties at the C-terminus as anticancer agents)

RN 213328-90-6 CAPLUS

CN L-Valinamide, N,N-dimethyl-L-valyl-N-methyl-N-[(1S)-2-methyl-1-[[(2S)-2-[[(2S)-2-(phenylacetyl)-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]carbonyl]propyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

L14	ANSWER 10 OF 38	CAPLUS	COPYRIGHT 2006	ACS on STN	
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9833797	A1	19980806	WO 1998-JP307	19980127

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

TW 577875	B	20040301	TW 1998-87101064	19980126
CA 2277947	AA	19980806	CA 1998-2277947	19980127
CA 2277947	C	20040921		
AU 9855775	A1	19980825	AU 1998-55775	19980127
AU 719210	B2	20000504		
BR 9807132	A	20000125	BR 1998-7132	19980127
EP 976748	A1	20000202	EP 1998-900741	19980127
EP 976748	B1	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 9901847	T2	20000621	TR 1999-9901847	19980127
RU 2198174	C2	20030210	RU 1999-119481	19980127
AT 255579	E	20031215	AT 1998-900741	19980127
PT 976748	T	20040331	PT 1998-900741	19980127
ES 2210710	T3	20040701	ES 1998-900741	19980127
US 6147100	A	20001114	US 1999-355008	19990722
NO 9903706	A	19990930	NO 1999-3706	19990729
NO 313881	B1	20021216		
MX 9907061	A	20000228	MX 1999-7061	19990729

IT **211297-41-5P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazolidinedione derivs. as phospholipase A2 inhibitors)

RN 211297-41-5 CAPLUS

CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-1-[2-(4-fluorobenzoyl)benzoyl]-2-[2-[4-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]phenyl]ethyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



=> d 11-16 pi fhitstr

L14 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967279	A1	19991229	WO 1999-EP4381	19990624
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19828114	A1	20000127	DE 1998-19828114	19980624
	CA 2335978	AA	19991229	CA 1999-2335978	19990624
	AU 9947772	A1	20000110	AU 1999-47772	19990624
	AU 758843	B2	20030403		
	BR 9911415	A	20010320	BR 1999-11415	19990624
	EP 1090030	A1	20010411	EP 1999-931163	19990624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002518518	T2	20020625	JP 2000-555930	19990624
	NZ 508721	A	20030630	NZ 1999-508721	19990624
	RU 2226195	C2	20040327	RU 2001-102057	19990624
	NO 2000006483	A	20001219	NO 2000-6483	20001219
	US 2001020006	A1	20010906	US 2000-745883	20001221


IT **186041-84-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of in the synthesis of prodrugs of unstable

dipeptidyl peptidase IV inhibitors)
 RN 186041-84-9 CAPLUS
 CN Pyridinium, 1-[2-oxo-2-[(2S)-1-[(2S)-1-oxo-3-phenyl-2-
 [(phenylmethoxy)carbonyl]amino]propyl]-2-pyrrolidinyl]ethyl]-, chloride
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

L14	ANSWER 12 OF 38	CAPLUS	COPYRIGHT 2006 ACS on STN		
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11246554	A2	19990914	JP 1998-375847	19981130
	JP 3174767	B2	20010611		
IT	243666-97-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of aromatic amidines as thrombin inhibitors)				
RN	243666-97-9	CAPLUS			
CN	1-Pyrrolidinebutanoic acid, α-(acetylamino)-2-[[[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, (αS,2R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L14 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055156	A1	20000921	WO 2000-KR216	20000315
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	KR 2000060566	A	20001016	KR 1999-8970	19990317
	JP 2002539210	T2	20021119	JP 2000-605585	20000315
	JP 3377989	B2	20030217		

IT 294658-79-OP


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted aromatic amidine derivs. as thrombin inhibitors)

RN 294658-79-0 CAPLUS

CN Carbamic acid, [(3S)-1-[2-[(2S)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-2-oxoethyl]hexahydro-2-oxo-1H-azepin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14	ANSWER 14 OF 38	CAPLUS	COPYRIGHT 2006 ACS on STN		
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038786	A2	20000706	WO 1999-US30692	19991222
	WO 2000038786	A3	20010308		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2356302	AA	20000706	CA 1999-2356302	19991222

AU 2000022104 A5 20000731 AU 2000-22104 19991222
 EP 1140179 A2 20011010 EP 1999-966594 19991222
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 TR 200102499 T2 20011221 TR 2001-200102499 19991222
 JP 2002533422 T2 20021008 JP 2000-590734 19991222
 EP 1522313 A1 20050413 EP 2004-26577 19991222
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI, RO, CY
 ZA 2001005055 A 20020920 ZA 2001-5055 20010620
 ZA 2001005120 A 20020107 ZA 2001-5120 20010621

IT **280105-30-8**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase-2 inhibitor and integrin antagonist in combination for neoplasia treatment)

RN 280105-30-8 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[1,3-dioxo-3-[2-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidiny]propyl]amino]-, (β S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038719	A1	20000706	WO 1999-US30700	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356402	AA	20000706	CA 1999-2356402	19991222
AU 2000027136	A5	20000731	AU 2000-27136	19991222
EP 1140183	A1	20011010	EP 1999-968942	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102499	T2	20011221	TR 2001-200102499	19991222
JP 2002533407	T2	20021008	JP 2000-590670	19991222
EP 1522313	A1	20050413	EP 2004-26577	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY				


ZA 2001005055 A 20020920 ZA 2001-5055 20010620
 ZA 2001005120 A 20020107 ZA 2001-5120 20010621

IT **280105-30-8**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (matrix metalloproteinase inhibitor and integrin antagonist in neoplasia treatment)

RN 280105-30-8 CAPLUS

CN 3-Pyridinepropanoic acid, β -[[[1,3-dioxo-3-[2-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]propyl]amino]-, (β S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038715	A2	20000706	WO 1999-US30621	19991222
WO 2000038715	A3	20010104		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2356748	AA	20000706	CA 1999-2356748	19991222
AU 2000022070	A5	20000731	AU 2000-22070	19991222
EP 1140177	A2	20011010	EP 1999-966558	19991222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200102499	T2	20011221	TR 2001-200102499	19991222
JP 2002533404	T2	20021008	JP 2000-590666	19991222
EP 1522313	A1	20050413	EP 2004-26577	19991222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY			
ZA 2001005055	A	20020920	ZA 2001-5055	20010620
ZA 2001005120	A	20020107	ZA 2001-5120	20010621
US 6689787	B1	20040210	US 2001-857871	20011005

IT **280105-30-8**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (integrin antagonist and radiation therapy combination for treatment of

neoplasia)
 RN 280105-30-8 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[1,3-dioxo-3-[2-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]propyl]amino]-, (BS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>

=> d 6 pi hitstr

L14	ANSWER 6 OF 38	CAPLUS	COPYRIGHT 2006	ACS on STN	
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9745424	A1	19971204	WO 1997-KR100	19970531
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9730494	A1	19980105	AU 1997-30494	19970531
	EP 918768	A1	19990602	EP 1997-925316	19970531
	EP 918768	B2	20020109		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1219932	A	19990616	CN 1997-195005	19970531
	CN 1079396	B	20020220		
	JP 2000504030	T2	20000404	JP 1997-542065	19970531
	JP 3202994	B2	20010827		
	AT 211741	E	20020115	AT 1997-925316	19970531
	ES 2171945	T3	20020916	ES 1997-925316	19970531
	CA 2256438	C	20021015	CA 1997-2256438	19970531
	CA 2256438	AA	19971204		
	US 6201006	B1	20010313	US 1998-180675	19981113
IT	200182-50-9P 200182-51-0P 200182-52-1P				
	200182-53-2P 200182-54-3P 200182-55-4P				
	200182-56-5P 200182-57-6P 200182-58-7P				
	200182-59-8P 200182-60-1P 200182-61-2P				
	200182-62-3P 200182-63-4P 200182-64-5P				
	200182-65-6P 200182-66-7P 200182-67-8P				
	200182-68-9P 200182-69-0P 200182-70-3P				
	200182-71-4P 200182-72-5P 200182-73-6P				

200182-74-7P 200182-75-8P 200182-77-0P
 200182-78-1P 200182-79-2P 200182-80-5P
 200182-82-7P 200182-83-8P 200182-84-9P
 200182-85-0P 200182-86-1P 200182-87-2P
 200182-88-3P 200182-89-4P 200182-90-7P
 200182-91-8P 200182-92-9P 200182-96-3P
 200182-97-4P 200182-98-5P 200182-99-6P
 200183-01-3P 200183-03-5P 200183-05-7P
 200183-06-8P 200183-07-9P 200183-08-0P
 200183-09-1P 200183-10-4P 200183-11-5P
 200183-12-6P 200183-13-7P 200183-14-8P
 200183-15-9P 200183-16-0P 200183-17-1P
 200183-18-2P 200183-19-3P 200183-20-6P
 200183-21-7P 200183-22-8P 200183-23-9P
 200183-24-0P 200183-25-1P 200183-26-2P
 200183-28-4P 200183-29-5P 200183-30-8P
 200183-31-9P 200183-32-0P 200183-33-1P
 200183-34-2P 200183-35-3P 200183-36-4P
 200183-37-5P 200183-38-6P 200183-39-7P
 200183-40-0P 200183-41-1P 200183-42-2P
 200183-43-3P 200183-44-4P 200183-45-5P
 200183-46-6P 200183-47-7P 200183-48-8P
 200183-49-9P 200183-50-2P 200183-51-3P
 200183-52-4P 200183-53-5P 200183-54-6P
 200183-55-7P 200183-56-8P 200183-57-9P
 200183-58-0P 200183-59-1P 200183-60-4P
 200183-61-5P 200183-62-6P 200183-63-7P
 200183-64-8P 200183-65-9P 200183-67-1P
 200183-68-2P 200183-69-3P 200183-70-6P
 200183-71-7P 200183-72-8P 200183-73-9P
 200183-74-0P 200183-75-1P 200183-76-2P
 200183-77-3P 200183-78-4P 200183-79-5P
 200183-80-8P 200183-81-9P 200183-82-0P
 200183-83-1P 200183-84-2P 200183-85-3P
 200183-86-4P 200183-87-5P 200183-88-6P
 200183-89-7P 200183-90-0P 200183-92-2P
 200183-93-3P 200183-94-4P 200183-95-5P
 200183-96-6P 200183-97-7P 200183-98-8P
 200183-99-9P 200184-00-5P 200186-61-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolecarboxamidines and analogs as thrombin inhibitors)

RN 200182-50-9 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-(4-methoxybenzoyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-51-0 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-(3,4-dimethoxybenzoyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-52-1 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-53-2 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-54-3 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[(3-chlorophenyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-55-4 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[(3-hydroxyphenyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-56-5 CAPLUS

CN Acetamide, 2-[3-[2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-57-6 CAPLUS

CN Acetic acid, [3-[2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-58-7 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[3-(trifluoromethyl)phenyl]acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-59-8 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[2-nitrophenyl]acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-60-1 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[2-[(methylsulfonyl)amino]phenyl]acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-61-2 CAPLUS

CN Benzoic acid, 2-[2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-, ethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-62-3 CAPLUS

CN Benzoic acid, 2-[2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-63-4 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(cyclopentylphenylacetyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-64-5 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(hydroxyphenylacetyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-65-6 CAPLUS

CN Acetamide, N-[2-[2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-1-(4-hydroxyphenyl)-2-oxoethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-66-7 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[(methylsulfonyl)amino]phenylacetyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-67-8 CAPLUS

CN Glycine, N-[(1R)-2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-68-9 CAPLUS

CN Acetamide, 2-[[2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxo-1-phenylethyl]amino]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-69-0 CAPLUS

CN Glycine, N-[(1R)-2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxo-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-70-3 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-(cyclopentylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-71-4 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(cyclopentylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-72-5 CAPLUS

CN 1-Pyrrolidinepropanoic acid, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-α-cyclopentyl-β-oxo-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-73-6 CAPLUS

CN 1-Pyrrolidinepropanoic acid, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-α-cyclopentyl-β-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-74-7 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(cyclohexylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-75-8 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(1-oxo-3-phenylpropyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-77-0 CAPLUS

CN Acetamide, N-[2-[2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxo-1-(phenylmethyl)ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-78-1 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[(cyclopropylamino)acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-79-2 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[cyclopropyl(methylsulfonyl)amino]acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-80-5 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-N-cyclopropyl-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200182-82-7 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-N-cyclopentyl-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200182-83-8 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-N-(phenylmethyl)-, ethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200182-84-9 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-N-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-85-0 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-86-1 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]-N-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-87-2 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-88-3 CAPLUS

CN Glycine, N-[(1R)-2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-89-4 CAPLUS

CN Glycine, N-[(1R)-2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-90-7 CAPLUS

CN Glycine, N-[(1R)-2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-91-8 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-β-(cyclopropylamino)-γ-oxo-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200182-92-9 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-β-(cyclopropylamino)-γ-oxo-, (2S)- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 200182-96-3 CAPLUS

CN Pyrrolidine, 1-acetyl-2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-97-4 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-[(phenylsulfonyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-98-5 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(2-pyrrolidinylcarbonyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200182-99-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-01-3 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-03-5 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-05-7 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-4-methyl-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2R-[1(R*),2 α ,4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-06-8 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-4-methyl-1-pyrrolidinyl]carbonyl]-, [2R-[1(R*),2 α ,4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-07-9 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-4-methoxy-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2R-[1(R*),2 α ,4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-08-0 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- α -methyl-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-09-1 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- α -ethyl-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-10-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- α -butyl-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-11-5 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-α-phenyl-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-12-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-α-(3-bromo-4-methoxyphenyl)-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-13-7 CAPLUS

CN 1-Pyrrolidineacetamide, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-14-8 CAPLUS

CN 1-Pyrrolidineacetamide, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-N-cyclopropyl-, [S-(R*,S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-15-9 CAPLUS

CN L-Alanine, N-[[[(2R)-2-[[[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]acetyl]]-, ethyl ester

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-16-0 CAPLUS

CN 1-Pyrrolidineacetamide, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-α-(2-hydroxyethyl)-, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-17-1 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-α-(2-hydroxyethyl)-, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-18-2 CAPLUS

CN Butanedioic acid, [2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]-, stereoisomer (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-19-3 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(tetrahydro-2-oxo-3-furanyl)-2-pyrrolidinyl]carbonyl]-, stereoisomer (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-20-6 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-21-7 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-22-8 CAPLUS

CN 1-Pyrrolidinepentanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-23-9 CAPLUS

CN 1-Pyrrolidinepentanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-24-0 CAPLUS

CN 1-Pyrrolidinehexanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-25-1 CAPLUS

CN 1-Pyrrolidinehexanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-26-2 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-4-methoxy-, ethyl ester, [2R-[2α(S*),4α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-28-4 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[2R]-1-(2-hydroxyethyl)-2-pyrrolidinyl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-29-5 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-[(methylamino)acetyl]-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-30-8 CAPLUS

CN Pyrrolidine, 1-(L-alanyl-D-prolyl)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-31-9 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(2-amino-1-oxobutyl)-2-pyrrolidinyl]carbonyl]-, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-32-0 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(L-valyl-D-prolyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-33-1 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[N-(methylsulfonyl)-L-alanyl-D-prolyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-34-2 CAPLUS

CN 1-Pyrrolidinebutanoic acid, β -amino-2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- γ -oxo-, ethyl

ester, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-35-3 CAPLUS

CN 1-Pyrrolidinebutanamide, β -amino-2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- γ -oxo-, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-36-4 CAPLUS

CN 1-Pyrrolidinebutanoic acid, β -amino-2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- γ -oxo-, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-37-5 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(3-amino-1-oxopropyl)-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-38-6 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(2-methyl-β-alanyl-D-prolyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-39-7 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(3-amino-1-oxobutyl)-2-pyrrolidinyl]carbonyl]-, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-40-0 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-[3-[(methylsulfonyl)amino]-1-oxopropyl]-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-41-1 CAPLUS

CN 1-Pyrrolidinebutanoic acid, α -amino-2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- γ -oxo-, ethyl ester, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-42-2 CAPLUS

CN 1-Pyrrolidinebutanamide, α -amino-2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- γ -oxo-, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-43-3 CAPLUS

CN 1-Pyrrolidinebutanoic acid, α -amino-2-[[[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- γ -oxo-, (α S,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-44-4 CAPLUS

CN 1-Pyrrolidinebutanamide, 2-[[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- α -[(methylsulfonyl)amino]- γ -oxo-, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-45-5 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]- α -[(methylsulfonyl)amino]- γ -oxo-, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-46-6 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(4-amino-1-oxobutyl)-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-47-7 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(2-piperidinylcarbonyl)-2-pyrrolidinyl]carbonyl]-, [2[R(S)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-48-8 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(3-piperidinylcarbonyl)-2-pyrrolidinyl]carbonyl]-, [3[R(S)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-49-9 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(4-piperidinylcarbonyl)-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-50-2 CAPLUS

CN Pyrrolidine, 1-acetyl-2-[[2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-51-3 CAPLUS

CN Pyrrolidine, 1-acetyl-2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-52-4 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(1-oxo-2-propylpentyl)-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-53-5 CAPLUS

CN 1-Pyrrolidinepropanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-β-oxo-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-54-6 CAPLUS

CN 1-Pyrrolidinepropanamide, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-β-oxo-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-55-7 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-γ-oxo-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-56-8 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-γ-oxo-, [S-(R*,S*)]-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-57-9 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(3-mercapto-1-oxopropyl)-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-58-0 CAPLUS


CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(3-hydroxy-1-oxobutyl)-2-pyrrolidinyl]carbonyl]-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-59-1 CAPLUS
 CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(1-oxo-2-propenyl)-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-60-4 CAPLUS
 CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-[[1-(methylsulfonyl)-2-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200183-61-5 CAPLUS
 CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-[[1-(methylsulfonyl)-2-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-62-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,R*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-63-7 CAPLUS

CN 1-Pyrrolidineacetamide, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-5-oxo-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-64-8 CAPLUS

CN Pyrrolidine, 2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(2-piperidinylcarbonyl)-, [2(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-65-9 CAPLUS

CN 1-Piperidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-67-1 CAPLUS

CN 1-Piperidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, methyl ester, [2(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-68-2 CAPLUS

CN 1-Piperidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, [2(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-69-3 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(3-piperidinylcarbonyl)-, [3(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-70-6 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-(4-piperidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-71-7 CAPLUS

CN L-Proline, 1-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-72-8 CAPLUS

CN L-Proline, 1-[2-[(2S)-2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-73-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-, ethyl ester, [1(S)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-74-0 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[2-[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]-, [1(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-75-1 CAPLUS

CN 1H-Indole-1-acetic acid, 2-[2-[1-[(1-acetyl-2-pyrrolidinyl)carbonyl]-2-pyrrolidinyl]ethyl]-6-(aminoiminomethyl)-, ethyl ester, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-76-2 CAPLUS

CN 1H-Indole-1-acetamide, 2-[2-[1-[(1-acetyl-2-pyrrolidinyl)carbonyl]-2-pyrrolidinyl]ethyl]-6-(aminoiminomethyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-77-3 CAPLUS

CN 1H-Indole-1-acetic acid, 2-[2-[1-[(1-acetyl-2-pyrrolidinyl)carbonyl]-2-pyrrolidinyl]ethyl]-6-(aminoiminomethyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200183-78-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[5-(aminoiminomethyl)-1-methyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-79-5 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[5-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200183-80-8 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-2-naphthalenyl]ethyl]-1-(phenylacetyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-81-9 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-2-naphthalenyl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-82-0 CAPLUS

CN Pyrrolidine, 2-[2-[7-(aminoiminomethyl)-2-naphthalenyl]ethyl]-1-(phenylacetyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-83-1 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[[2-[2-[7-(aminoiminomethyl)-2-naphthalenyl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [R-(R*,R*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-84-2 CAPLUS

CN Pyrrolidine, 2-[2-[5-(aminoiminomethyl)-2-benzofuranyl]ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-85-3 CAPLUS

CN Pyrrolidine, 2-[2-[5-(aminoiminomethyl)-2-benzofuranyl]ethenyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 200183-86-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[5-(aminoiminomethyl)-2-benzofuranyl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-87-5 CAPLUS

CN 1-Pyrrolidineacetamide, 2-[[2-[2-[6-(aminoiminomethyl)-2-benzofuranyl]ethyl]-1-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-88-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-3-methyl-2-benzofuranyl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-89-7 CAPLUS

CN Pyrrolidine, 2-[2-[5-(aminoiminomethyl)benzo[b]thien-2-yl]ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-90-0 CAPLUS

CN Pyrrolidine, 2-[2-[6-(aminoiminomethyl)-3-methoxybenzo[b]thien-2-yl]ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-92-2 CAPLUS

CN Pyrrolidine, 2-[2-[1-ethyl-6-[(hydroxyamino)iminomethyl]-1H-indol-2-yl]ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-93-3 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[1-ethyl-6-[(hydroxyamino)iminomethyl]-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-94-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[1-ethyl-6-[[imino[(methoxycarbonyl)amino]methyl]-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-95-5 CAPLUS

CN Carbamic acid, [[1-ethyl-2-[2-[1-(phenylacetyl)-2-pyrrolidinyl]ethyl]-1H-indol-6-yl]iminomethyl]-, ethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-96-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-[(ethoxycarbonyl)amino]iminomethyl]-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-97-7 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[1-ethyl-6-[imino[(2-methylpropoxy)carbonyl]amino]methyl]-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-98-8 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[1-ethyl-6-[(2,2,2-trichloroethoxy)carbonyl]amino]methyl]-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200183-99-9 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[1-ethyl-6-[imino[(phenoxy)carbonyl]amino]methyl]-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-00-5 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-α-(cyclopropylamino)-γ-oxo-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200186-61-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]carbonyl]-5-oxo-, [S-(R*,S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 200184-12-9P 200184-13-0P 200184-14-1P
 200184-15-2P 200184-16-3P 200184-17-4P
 200184-18-5P 200184-19-6P 200184-20-9P
 200184-21-0P 200184-22-1P 200184-23-2P
 200184-24-3P 200184-25-4P 200184-27-6P
 200184-29-8P 200184-31-2P 200184-32-3P
 200184-33-4P 200184-34-5P 200184-35-6P
 200184-36-7P 200184-37-8P 200184-40-3P
 200184-41-4P 200184-42-5P 200184-43-6P
 200184-44-7P 200184-52-7P 200184-65-2P
 200184-66-3P 200184-67-4P 200184-72-1P
 200184-73-2P 200184-74-3P 200184-75-4P
 200184-76-5P 200184-77-6P 200184-78-7P
 200184-80-1P 200184-81-2P 200184-82-3P
 200184-83-4P 200184-84-5P 200184-85-6P
 200184-88-9P 200184-89-0P 200184-90-3P
 200184-95-8P 200184-96-9P 200184-97-0P
 200184-98-1P 200184-99-2P 200185-00-8P
 200185-01-9P 200185-02-0P 200185-03-1P
 200185-04-2P 200185-05-3P 200185-06-4P
 200185-07-5P 200185-08-6P 200185-09-7P
 200185-10-0P 200185-11-1P 200185-12-2P
 200185-13-3P 200185-14-4P 200185-15-5P
 200185-16-6P 200185-17-7P 200185-18-8P
 200185-19-9P 200185-20-2P 200185-21-3P
 200185-22-4P 200185-23-5P 200185-24-6P
 200185-25-7P 200185-26-8P 200185-27-9P
 200185-28-0P 200185-29-1P 200185-30-4P

200185-34-8P 200185-35-9P 200185-36-0P
 200185-37-1P 200185-38-2P 200185-42-8P
 200185-43-9P 200185-50-8P 200185-51-9P
 200185-52-0P 200185-60-0P 200185-61-1P
 200185-62-2P 200185-65-5P 200185-66-6P
 200185-69-9P 200185-71-3P 200185-76-8P
 200185-78-0P 200185-79-1P 200185-80-4P
 200185-81-5P 200185-88-2P 200185-89-3P
 200185-90-6P 200185-97-3P 200185-98-4P
 200186-02-3P 200186-13-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of indolecarboxamidines and analogs as thrombin inhibitors)

RN 200184-12-9 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-(4-methoxybenzoyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-13-0 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-(3,4-dimethoxybenzoyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-14-1 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-15-2 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[[3-[[[(1,1-dimethylethyl)dimethylsilyloxy]phenyl]acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-16-3 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[(3-hydroxyphenyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-17-4 CAPLUS

CN Acetic acid, [3-[2-[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-2-oxoethyl]phenoxy]-, ethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-18-5 CAPLUS

CN Benzoic acid, 2-[2-[2-(2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl)-1-pyrrolidinyl]-2-oxoethyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-19-6 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-(cyclopentylphenylacetyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-20-9 CAPLUS

CN Pyrrolidine, 1-(aminophenylacetyl)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-21-0 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-(cyclopentylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-22-1 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-(cyclopentylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-23-2 CAPLUS

CN 1-Pyrrolidinepropanoic acid, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-α-cyclopentyl-β-oxo-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-24-3 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-(cyclohexylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-25-4 CAPLUS

CN Pyrrolidine, 1-(chloroacetyl)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-27-6 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-2-oxoethyl]-N-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-29-8 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[2-(cyclopropylamino)-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-31-2 CAPLUS

CN Glycine, N-[2-[(2S)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]-N-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-32-3 CAPLUS

CN Carbamic acid, [2-[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-33-4 CAPLUS

CN Glycine, N-[(1R)-2-[(2S)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-34-5 CAPLUS

CN Carbamic acid, [2-[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-35-6 CAPLUS

CN Glycine, N-[(1R)-2-[(2S)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-36-7 CAPLUS

CN Carbamic acid, [2-[[2-[[2-[6-(aminoiminomethyl)-1-ethyl-1H-indol-2-yl]ethyl]-1-pyrrolidinyl]-2-oxoethyl]cyclopropyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-37-8 CAPLUS


CN 1-Pyrrolidinebutanoic acid, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-β-[cyclopropyl[(1,1-dimethylethoxy)carbonyl]amino]-γ-oxo-, ethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-40-3 CAPLUS
 CN Pyrrolidine, 2-[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-
 [(phenylsulfonyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-41-4 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[(2S)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-42-5 CAPLUS
 CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[(2R)-2-pyrrolidinylcarbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-43-6 CAPLUS
 CN Pyrrolidine, 2-[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-[(2R)-2-pyrrolidinylcarbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-44-7 CAPLUS
 CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, methyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200184-52-7 CAPLUS
 CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-65-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-4-methyl-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [2R-[1(R*),2 α ,4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-66-3 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-4-methyl-1-(2-pyrrolidinylcarbonyl)-, [2R-[1(R*),2 α ,4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-67-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-4-methyl-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2R-[1(R*),2 α ,4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-72-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-4-methoxy-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [2R-[1(R*),2α,4α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-73-2 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-4-methoxy-1-(2-pyrrolidinylcarbonyl)-, [2R-[1(R*),2α,4α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-74-3 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-4-methoxy-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2R-[1(R*),2α,4α]]-

[1(R*),2 α ,4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-75-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]- α -methyl-, ethyl ester, [2S-[1(2S*),2R*]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-76-5 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]- α -ethyl-, ethyl ester, [2S-[1(2S*),2R*]]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-77-6 CAPLUS

CN 1-Pyrrolidineacetic acid, α -butyl-2-[[2-[2-(6-cyano-1-ethyl-1H-indol-

2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2S-[1(2S*),2R*]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-78-7 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-α-phenyl-, ethyl ester, [2S-[1(2S*),2R*]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-80-1 CAPLUS

CN 1-Pyrrolidineacetic acid, α-(3-bromo-4-methoxyphenyl)-2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2S-[1(2S*),2R*]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-81-2 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[[1-(tetrahydro-2-oxo-3-furanyl)-2-pyrrolidinyl]carbonyl]-, [2S-[1(2S*),2R*]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-82-3 CAPLUS

CN Butanedioic acid, [2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]-, diethyl ester, [2R-[2R*(S*)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-83-4 CAPLUS

CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-84-5 CAPLUS

CN 1-Pyrrolidinepentanoic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-85-6 CAPLUS

CN 1-Pyrrolidinehexanoic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200184-88-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-4-methoxy-, 1,1-dimethylethyl ester,

[2R-[2 α (S*),4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-89-0 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[(4-methoxy-2-pyrrolidinyl)carbonyl]-, [2R-[2 α (S*),4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-90-3 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-4-methoxy-, ethyl ester, [2R-[2 α (S*),4 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-95-8 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[[1-(2-hydroxyethyl)-2-pyrrolidinyl]carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-96-9 CAPLUS

CN Carbamic acid, [2-[2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-97-0 CAPLUS

CN Carbamic acid, [2-[2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-98-1 CAPLUS

CN Carbamic acid, [1-[[2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]carbonyl]propyl]-, 1,1-dimethylethyl ester, [2R-[2R*(S*)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200184-99-2 CAPLUS

CN Carbamic acid, [1-[[2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-00-8 CAPLUS

CN Pyrrolidine, 1-(L-alanyl-D-prolyl)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200185-01-9 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[N-(methylsulfonyl)-L-alanyl-D-prolyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 200185-05-3 CAPLUS

CN Carbamic acid, [3-[2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester, [2S-[1(2S*),2R*]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-06-4 CAPLUS

CN Carbamic acid, [3-[2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-07-5 CAPLUS

CN Pyrrolidine, 1-(β -alanyl-D-prolyl)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-08-6 CAPLUS


CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]- α -[[[(1,1-dimethylethoxy)carbonyl]amino]- γ -oxo-, phenylmethyl ester, [2S-[1[S*(R*)],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-09-7 CAPLUS
 CN 1-Pyrrolidinebutanoic acid, α -amino-2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]- γ -oxo-, phenylmethyl ester, [2S-[1S*(R*)],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-10-0 CAPLUS
 CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]- α -[(methylsulfonyl)amino]- γ -oxo-, phenylmethyl ester, [2S-[1S*(R*)],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200185-11-1 CAPLUS
 CN Carbamic acid, [4-[2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]-4-oxobutyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-12-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[2-[[2-[[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [2[R(S)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-13-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[2-[[2-[[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [3[R(S)]]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-14-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[2-[[2-[[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-15-5 CAPLUS
 CN Pyrrolidine, 1-acetyl-2-[[2-[[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-16-6 CAPLUS
 CN Pyrrolidine, 1-acetyl-2-[[2-[[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-17-7 CAPLUS
 CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[[1-(1-oxo-2-propylpentyl)-2-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-18-8 CAPLUS
 CN 1-Pyrrolidinepropanoic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-β-oxo-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200185-19-9 CAPLUS
 CN 1-Pyrrolidinebutanoic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-γ-oxo-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-20-2 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[[1-(3-mercapto-1-oxopropyl)-2-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-21-3 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[[1-(3-hydroxy-1-oxobutyl)-2-pyrrolidinyl]carbonyl]-, stereoisomer (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-22-4 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-[[1-(methylsulfonyl)-2-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-23-5 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[[1-(methylsulfonyl)-2-pyrrolidinyl]carbonyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-24-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-25-7 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-(2-pyrrolidinylcarbonyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-26-8 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-27-9 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-[(5-oxo-2-pyrrolidinyl)carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-28-0 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-5-oxo-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-29-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [2(S)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-30-4 CAPLUS

CN 1-Piperidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [2(S)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-34-8 CAPLUS

CN 1-Piperidineacetic acid, 2-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, methyl ester, [2(S)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-35-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [3(S)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-36-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-37-1 CAPLUS

CN L-Proline, 1-[2-[(2S)-2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-38-2 CAPLUS

2-Piperidinecarboxylic acid, 1-[2-[2-[2-(6-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]-2-oxoethyl]-, ethyl ester, [1(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-42-8 CAPLUS

1H-Indole-1-acetic acid, 6-cyano-2-[2-[1-[[1-[(1,1-dimethylethoxy)carbonyl]-2-pyrrolidinyl]carbonyl]-2-pyrrolidinyl]ethyl]-, ethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-43-9 CAPLUS

CN 1H-Indole-1-acetic acid, 2-[2-[1-[(1-acetyl-2-pyrrolidinyl)carbonyl]-2-pyrrolidinyl]ethyl]-6-cyano-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-50-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(5-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-51-9 CAPLUS

CN Pyrrolidine, 2-[2-(5-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-(2-pyrrolidinylcarbonyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-52-0 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(5-cyano-1-methyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-60-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(5-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-61-1 CAPLUS

CN Pyrrolidine, 2-[2-(5-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-(2-pyrrolidinylcarbonyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-62-2 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(5-cyano-1-ethyl-1H-indol-2-yl)ethyl]-1-

pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-65-5 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-2-naphthalenyl)ethyl]-1-(phenylacetyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-66-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-2-naphthalenyl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-69-9 CAPLUS

CN Pyrrolidine, 2-[2-(7-cyano-2-naphthalenyl)ethyl]-1-(phenylacetyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-71-3 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(7-cyano-2-naphthalenyl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-76-8 CAPLUS

CN Pyrrolidine, 2-[2-(5-ethynyl-2-benzofuranyl)ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-78-0 CAPLUS

CN Pyrrolidine, 2-[2-(5-cyano-2-benzofuranyl)ethenyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 200185-79-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(5-cyano-2-benzofuranyl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-80-4 CAPLUS
 CN Pyrrolidine, 2-[2-(5-cyano-2-benzofuranyl)ethyl]-1-(2-pyrrolidinylcarbonyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200185-81-5 CAPLUS
 CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(5-cyano-2-benzofuranyl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200185-88-2 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[2-[2-(6-cyano-2-benzofuranyl)ethyl]-1-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-89-3 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-2-benzofuranyl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-90-6 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-[6-(aminoiminomethyl)-2-benzofuranyl]ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-97-3 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-3-methyl-2-benzofuranyl)ethyl]-1-(2-pyrrolidinylcarbonyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200185-98-4 CAPLUS

CN 1-Pyrrolidineacetic acid, 2-[[2-[2-(6-cyano-3-methyl-2-benzofuranyl)ethyl]-1-pyrrolidinyl]carbonyl]-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200186-02-3 CAPLUS

CN Pyrrolidine, 2-[2-(5-cyanobenzo[b]thien-2-yl)ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200186-13-6 CAPLUS

CN Pyrrolidine, 2-[2-(6-cyano-3-methoxybenzo[b]thien-2-yl)ethyl]-1-(phenylacetyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




=> d 10 pi hitstr

L14 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833797	A1	19980806	WO 1998-JP307	19980127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 577875	B	20040301	TW 1998-87101064	19980126
CA 2277947	AA	19980806	CA 1998-2277947	19980127
CA 2277947	C	20040921		
AU 9855775	A1	19980825	AU 1998-55775	19980127
AU 719210	B2	20000504		
BR 9807132	A	20000125	BR 1998-7132	19980127
EP 976748	A1	20000202	EP 1998-900741	19980127
EP 976748	B1	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 9901847	T2	20000621	TR 1999-9901847	19980127
RU 2198174	C2	20030210	RU 1999-119481	19980127
AT 255579	E	20031215	AT 1998-900741	19980127
PT 976748	T	20040331	PT 1998-900741	19980127
ES 2210710	T3	20040701	ES 1998-900741	19980127
US 6147100	A	20001114	US 1999-355008	19990722
NO 9903706	A	19990930	NO 1999-3706	19990729
NO 313881	B1	20021216		
MX 9907061	A	20000228	MX 1999-7061	19990729
IT 211297-41-5P 211297-45-9P 211297-48-2P 211297-52-8P 211297-55-1P 211297-57-3P 211297-59-5P 211297-62-0P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of thiazolidinedione derivs. as phospholipase A2 inhibitors)				
RN 211297-41-5	CAPLUS			
CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-1-[2-(4-fluorobenzoyl)benzoyl]-2-[2-[4-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]phenyl]ethyl]-, (2R,4R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


Double bond geometry unknown.



RN 211297-45-9 CAPLUS

CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-2-[2-[4-[(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]ethyl]-1-[2-(4-fluorobenzoyl)benzoyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 211297-48-2 CAPLUS

CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-1-[2-(4-


fluorobenzoyl)benzoyl]-2-[2-[4-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]phenyl]ethenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 211297-52-8 CAPLUS
CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-2-[2-[4-[(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl]ethenyl]-1-[2-(4-fluorobenzoyl)benzoyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 211297-55-1 CAPLUS

CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-1-[2-(4-fluorobenzoyl)benzoyl]-2-[(1Z)-2-[5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-2-thienyl]ethenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.



RN 211297-57-3 CAPLUS
 CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-2-[(1Z)-2-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2-thienyl]ethenyl]-1-[2-(4-fluorobenzoyl)benzoyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as described by E or Z.



RN 211297-59-5 CAPLUS
 CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-1-[2-(4-fluorobenzoyl)benzoyl]-2-[(1E)-2-[5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-2-thienyl]ethenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




RN 211297-62-0 CAPLUS

CN Pyrrolidine, 4-([1,1'-biphenyl]-2-ylmethoxy)-2-[(1E)-2-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2-thienyl]ethenyl]-1-[2-(4-fluorobenzoyl)benzoyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



=> logoff

10/686,871

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD: .
STN INTERNATIONAL LOGOFF AT 15:05:22 ON 20 JAN 2006